• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

紫杉醇、卡铂和曲妥珠单抗。

Paclitaxel, Carboplatin, and trastuzumab.

作者信息

Lee Jennifer, Solimando Dominic A, Waddell J Aubrey

机构信息

Dr. Lee is a pharmacist at Mirixa Corporation, Reston, Virginia. At the time this article was written, she was a student at the University of Maryland, School of Pharmacy , Baltimore, Maryland.

出版信息

Hosp Pharm. 2014 Nov;49(10):913-9. doi: 10.1310/hpj4910-913.

DOI:10.1310/hpj4910-913
PMID:25477563
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4252214/
Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

摘要

癌症化疗的复杂性要求药剂师熟悉所使用的复杂治疗方案和高毒性药物。本专栏回顾了与抗肿瘤治疗的制备、调配和给药相关的各种问题,以及用于治疗恶性疾病的市售和研究性药物。有关主题的问题或建议,请致函肿瘤药学服务公司总裁小多米尼克·A·索利曼多,地址为弗吉尼亚州阿灵顿市威尔逊大道4201号#110 - 545,邮编22203,电子邮件:OncRxSvc@comcast.net;或致函田纳西大学药学院教授J·奥布里·沃德尔;布朗特纪念医院药房肿瘤药剂师,地址为田纳西州玛丽维尔市东拉马尔·亚历山大大道907号,邮编37804,电子邮件:waddfour@charter.net。

相似文献

1
Paclitaxel, Carboplatin, and trastuzumab.紫杉醇、卡铂和曲妥珠单抗。
Hosp Pharm. 2014 Nov;49(10):913-9. doi: 10.1310/hpj4910-913.
2
Carboplatin and Liposomal Doxorubicin for Ovarian Cancer.卡铂和脂质体阿霉素用于治疗卵巢癌。
Hosp Pharm. 2016 Jun;51(6):442-9. doi: 10.1310/hpj5106-442.
3
Dinutuximab and Panobinostat.地努图希单抗和帕比司他。
Hosp Pharm. 2015 Oct;50(9):767-72. doi: 10.1310/hpj5009-767. Epub 2015 Oct 14.
4
Blinatumomab and Pembrolizumab.博纳吐单抗和帕博利珠单抗。
Hosp Pharm. 2015 Apr;50(4):269-73. doi: 10.1310/hpj5004-269. Epub 2015 Apr 8.
5
Nab-Paclitaxel and Carboplatin (Nab-PC) Regimen for Advanced Non-Small-Cell Lung Cancer.纳武单抗联合卡铂(Nab-PC)方案用于晚期非小细胞肺癌
Hosp Pharm. 2014 Oct;49(9):804-8. doi: 10.1310/hpj4909-804.
6
Drug Monographs: Ixazomib and Necitumumab.药品专论:伊沙佐米和奈昔妥珠单抗。
Hosp Pharm. 2016 May;51(5):362-6. doi: 10.1310/hpj5105-362.
7
Alectinib, Ceritinib, Elotuzumab, and Venetoclax.阿来替尼、色瑞替尼、埃罗妥珠单抗和维奈托克。
Hosp Pharm. 2016 Jul;51(7):524-34. doi: 10.1310/hpj5107-524.
8
Gefitinib and Sonidegib.吉非替尼和索尼德吉。
Hosp Pharm. 2015 Nov;50(10):868-872. doi: 10.1310/hpj5010-868. Epub 2015 Nov 19.
9
Paclitaxel and trastuzumab for breast cancer.紫杉醇和曲妥珠单抗用于治疗乳腺癌。
Hosp Pharm. 2014 Apr;49(4):338-44. doi: 10.1310/hpj4904-338.
10
Doxorubicin and Dacarbazine (AD) Regimen for Soft Tissue Sarcomas.多柔比星与达卡巴嗪(AD)联合方案治疗软组织肉瘤
Hosp Pharm. 2015 Mar;50(3):194-8. doi: 10.1310/hpj5003-194.

引用本文的文献

1
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients.曲妥珠单抗联合辅助化疗治疗人表皮生长因子受体2(HER2)阳性早期乳腺癌:一项针对中国患者的真实世界回顾性研究。
Chin J Cancer Res. 2019 Oct;31(5):759-770. doi: 10.21147/j.issn.1000-9604.2019.05.06.

本文引用的文献

1
Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.紫杉醇、卡铂和曲妥珠单抗联合新辅助方案治疗 HER2 阳性乳腺癌。
Breast J. 2013 Jul-Aug;19(4):419-26. doi: 10.1111/tbj.12124. Epub 2013 May 20.
2
Weekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule.每周紫杉醇/卡铂/曲妥珠单抗治疗与每 3 周一次的方案相比,可改善侵袭性 HER2 阳性乳腺癌的病理完全缓解率,尤其是在 luminal-B 亚型中。
Oncologist. 2013;18(5):511-7. doi: 10.1634/theoncologist.2012-0057. Epub 2013 May 1.
3
Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors.采用 CKD-EPI 和 Cockcroft-Gault 公式并结合不同体重描述符计算低血清肌酐浓度肺癌患者的卡铂剂量。
Lung Cancer. 2013 Jan;79(1):54-8. doi: 10.1016/j.lungcan.2012.10.009. Epub 2012 Nov 4.
4
Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.一项针对人表皮生长因子受体 2(HER2)过表达转移性乳腺癌女性患者的一线治疗方案,即每周给予纳米白蛋白结合紫杉醇联合卡铂和曲妥珠单抗治疗的Ⅱ期临床试验。
Clin Breast Cancer. 2010 Aug 1;10(4):281-7. doi: 10.3816/CBC.2010.n.036.
5
Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study.每4周使用卡铂联合每周使用紫杉醇(加或不加曲妥珠单抗)治疗侵袭性II至III期乳腺癌时频繁出现病理完全缓解:布朗大学肿瘤学组研究
J Clin Oncol. 2009 Oct 1;27(28):4693-700. doi: 10.1200/JCO.2008.21.4163. Epub 2009 Aug 31.
6
Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?对于肾功能正常的超重和肥胖患者,卡铂给药剂量与体重有关吗?
Cancer Chemother Pharmacol. 2009 Jun;64(1):115-22. doi: 10.1007/s00280-008-0856-x. Epub 2008 Nov 7.
7
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study.一项随机III期研究,比较三种不含蒽环类药物的紫杉烷类方案作为转移性乳腺癌一线化疗方案:一项希腊合作肿瘤学组研究。
Breast Cancer Res Treat. 2009 May;115(1):87-99. doi: 10.1007/s10549-008-0047-9. Epub 2008 May 16.
8
Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer.曲妥珠单抗、紫杉醇和卡铂每周给药方案,每28天休息一周用于HER2阳性转移性乳腺癌的II期研究。
Cancer Chemother Pharmacol. 2008 Nov;62(6):1085-90. doi: 10.1007/s00280-008-0709-7. Epub 2008 Mar 26.
9
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.曲妥珠单抗、紫杉醇和卡铂与曲妥珠单抗和紫杉醇对比治疗HER-2过表达转移性乳腺癌女性患者的随机III期研究。
J Clin Oncol. 2006 Jun 20;24(18):2786-92. doi: 10.1200/JCO.2005.04.1764.
10
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.白细胞生长因子使用建议的2006年更新:基于证据的临床实践指南
J Clin Oncol. 2006 Jul 1;24(19):3187-205. doi: 10.1200/JCO.2006.06.4451. Epub 2006 May 8.